RxDoctor Payments Data

Sarah Logan, PA

Physician Assistant · London, KYNPI 1275248080

Payments from drug & device makers

$4,443in general payments, 2019–2025

Across 236 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$709
  • Novartis$545
  • Pfizer$534
  • AstraZeneca$503
  • Bayer$433
  • Lilly USA, LLC$347
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$4,443100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,443 in reported general payments places this provider in the 90th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$42,737
Medicare patients
252
Services billed
2,800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$38,673
EliquisApixaban41$33,718
JardianceEmpagliflozin30$26,393
MounjaroTirzepatide25$25,982
RybelsusSemaglutide15$16,784
EntrestoSacubitril/Valsartan15$10,688
TrulicityDulaglutide11$10,670
LinzessLinaclotide11$7,813
PaxlovidNirmatrelvir/Ritonavir22$1,364
Levothyroxine Sodium116$1,241
SynthroidLevothyroxine Sodium29$1,136
Valsartan32$842
Esomeprazole Magnesium13$784
Metoprolol Succinate61$687
Ventolin HfaAlbuterol Sulfate11$615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$709$55,45854 claims
Lilly USA, LLCMounjaro, Trulicity$347$36,65236 claims
PfizerEliquis, Paxlovid$534$35,08263 claims
Boehringer IngelheimJardiance$41$26,39330 claims
NovartisEntresto$545$10,68815 claims
AbbVieLinzess, Synthroid$232$8,94940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in London

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →